Skip to main content
IRLAB Therapeutics logo

IRLAB Therapeutics — Investor Relations & Filings

Ticker · IRLAB ISIN · SE0012675361 LEI · 549300JAT34LHEI0DH60 ST Manufacturing
Open in API
Filings indexed 161 across all filing types
Latest filing 2026-06-05 Capital/Financing Update
Country SE Sweden
Listing ST IRLAB

About IRLAB Therapeutics

https://irlab.se/

IRLAB Therapeutics is a research and development company that discovers and develops novel treatments for neurodegenerative diseases, with a primary focus on Parkinson's disease and other central nervous system (CNS) disorders. The company's research originates from Nobel Prize-winning science and is driven by its proprietary Integrative Screening Process (ISP) platform. This systems pharmacology-based discovery engine utilizes an extensive database to generate a pipeline of drug candidates. The company's portfolio includes clinical-stage assets such as Mesdopetam (IRL790), in development for treating levodopa-induced dyskinesia (LIDs), and Pirepemat (IRL752), which is being developed to reduce falls and improve balance in patients with Parkinson's disease.

Recent filings

Filing Released Lang Actions
IRLAB offentliggör informationsdokument i samband med företrädesemissionen och meddelar att ytterligare teckningsåtaganden erhållits
Capital/Financing Update Classification · 90% confidence The document is a press release announcing a rights issue (företrädesemission) and disclosing that an information document has been prepared and made available, along with subscription undertakings received. It provides terms of the new share issue, over‐allotment, timeline, and advisor information. This is a Capital/Financing Update rather than the actual information document or a regulatory filing per se.
2026-06-05 Swedish
IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received
Share Issue/Capital Change Classification · 82% confidence The document is a press release announcing a rights issue of new shares (ordinary shares series A), detailing subscription undertakings, timeline, and terms of the Rights Issue and Overallotment Issue. This is a new share issuance announcement (capital change). It focuses on fundraising via a rights issue rather than providing full financial statements or performance data. Therefore, it best fits the Share Issue/Capital Change category (SHA).
2026-06-05 English
Kommuniké från extra bolagsstämma i IRLAB Therapeutics AB
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a press release summarizing the outcomes of an extra general meeting (extra bolagsstämma) at IRLAB Therapeutics AB. It details the voting results on several resolutions (share issues, amendment of articles, board elections, fees). This is exactly a Declaration of Voting Results & Voting Rights Announcement, matching category DVA.
2026-06-05 Swedish
Report from the Extraordinary General Meeting of IRLAB Therapeutics AB
Declaration of Voting Results & Voting Rights Announcements Classification · 88% confidence The document is a press release detailing the resolutions adopted at an Extraordinary General Meeting (EGM), including share issue approvals, amendments to the articles of association, and election of new board members. It reports the outcomes of shareholder votes at the meeting, rather than soliciting votes or providing full meeting materials. Therefore it best fits the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-06-05 English
KALLELSE TILL ÅRSSTÄMMA I IRLAB THERAPEUTICS AB
Proxy Solicitation & Information Statement Classification · 87% confidence The document is a formal notice (‘kallelse’) to the Annual General Meeting, including the agenda, proposals for election of board members, resolutions on remuneration, share issues and instructions on how shareholders may register and vote. It is not the annual report itself, nor a mere publication announcement, but rather the proxy solicitation/information statement sent to shareholders to request votes at the AGM. Therefore it best fits the Proxy Solicitation & Information Statement category (PSI).
2026-05-29 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport januari – mars 2026' which translates to 'Interim Report January – March 2026'. It contains detailed financial data for the first quarter of 2026, including net sales, operating results, earnings per share, cash flow, and employee numbers. It also includes management commentary, strategic priorities, and operational updates. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content is consistent with a quarterly or interim financial report providing substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.